{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["nivolumab"]],"indication":"androgen receptor pathway inhibitor-pretreated metastatic castration-resistant prostate cancer","name":"CheckMate 7DX","nct_id":"NCT04100018","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-7dx-nct04100018. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate 7DX","arms":[{"description":null,"label":"Arm A: Nivolumab + docetaxel + prednisone","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B: Placebo + docetaxel + prednisone","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-06-25","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":1030,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["OPDIVO,","BMS-936558-01"],"type":"BIOLOGICAL"},{"name":"Prednisone","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2025-06-12","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-06-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)","timeFrame":"from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)"},{"measure":"Overall Survival (OS)","timeFrame":"From randomization to the date of death from any cause (Up to approximately 31 months)"}],"references":[{"citation":"Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthelemy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhofer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):68-78. doi: 10.1016/S1470-2045(25)00566-2.","pmid":"41449150","type":"DERIVED"}],"start_date":{"date":"2020-02-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04100018"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-7dx-nct04100018"}